Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well RO4929097 (gamma-secretase/Notch signalling pathway
inhibitor RO4929097) works in treating patients with previously treated metastatic pancreatic
cancer. RO4929097 may stop the growth of tumor cells by blocking some enzymes needed for cell
growth.